Showing chemical card for Elacytarabine (CFc000323743)
| Record Information | |
|---|---|
| Version | 1.0 |
| Creation Date | 2022-09-06 19:45:53 UTC |
| Update Date | 2022-09-14 04:54:56 UTC |
| Chemfont ID | CFc000323743 |
| Molecule Identification | |
| Common Name | Elacytarabine |
| Definition | Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia. Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells. Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological properties and the potential to treat solid tumours such as non-small cell lung cancer, malignant melanoma and ovarian cancer. |
| Structure |  |
| Synonyms | Not Available |
| Chemical Formula | |
| Average Molecular Weight | |
| Monoisotopic Molecular Weight | |
| IUPAC Name | |
| Traditional Name | |
| CAS Registry Number | 188181-42-2 |
| SMILES | Not Available |
| InChI Identifier | |
| InChI Key | |
| Chemical Taxonomy | |
| Classification | Not classified |
| Functional Ontology | |
| Physiological effect | Not Available |
| Disposition | |
| Process | Not Available |
| Role | Not Available |
| Physical Properties | |
| Predicted Properties | Not Available |
| External Links | |
| External Links | Not Available |
| References | |
| Synthesis Reference | Not Available |